The dramatic growth of a key federal drug discount program has fueled debate about whether it is helping low-income patients as intended or primarily benefiting health care providers.

A new pilot program from the federal government has hospital and pharmacy leaders bracing for what they describe as a fundamental dismantling of the ...

Congress appears to be inching toward injecting more transparency into a controversial program that forces drugmakers to give safety-net hospitals steep discounts on drugs. It would be a win for ...

Several recent policy proposals are placing new pressures on the 340B drug pricing program, a decades-old federal initiative many hospitals and health systems depend on to offset the costs of care for ...

The dramatic growth of a key federal drug discount program has fueled debate about whether it is helping low-income patients as intended or primarily ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The 340B Drug Pricing Program has long been a contentious ...

The 340B drug discount program would work better if the money followed the patient rather than going directly to hospitals, Anthony DiGiorgio, DO, MHA, said Monday at an event on 340B sponsored by the ...

Americans assume hospitals are in the business of keeping us healthy, not of buying drugs inexpensively and then reselling ...

The core problem in 340B runs deeper than poor oversight. The law requires steep discounts for purchased drugs but does not specify that the savings should be passed on to patients and insurance ...

The Health Resources & Services Administration (HRSA), the agency charged with administering 340B, sent letters to each company, now over 30, telling them they are violating program guidelines and the ...